Drugs / CE211NS21
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07595965 | Dec 2026 → Dec 2027 expected | neuromyelitis optica spectrum disorder with anti-AQP4 antibodies | Corestemchemon, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-26 | Corestemchemon, Inc. | Regulatory 코아스템켐온,시신경 척수염 환자 1/2a상 임상시험계획 승인 신청 corestemchemon.com ↗
코아스템켐온(주)은 항아쿠아포린4 항체 양성 시신경척수염 범주질환 환자에서 동종골수유래 중간엽줄기세포(CE211NS21)와 면역억제제(Immunosuppressive Therapy, IST) 병용치료 시 안전성 및 유효성을 평가하기 위한 제1/2a상 임상시험계획 승인을 26일 신청했다고 공시했다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-26 | Corestemchemon, Inc. | 코아스템켐온,시신경 척수염 환자 1/2a상 임상시험계획 승인 신청 corestemchemon.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CE211NS21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07595965 ↗ |
| Modality | Cell therapy | “allogeneic bone marrow-derived mesenchymal stem cells” NCT07595965 ↗ |
| Route | Intrathecal | “intrathecal administration of CE211NS21” NCT07595965 ↗ |